| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Immunovant Inc. | IMVT-1401 (ASCEND GO-2) | Graves Ophthalmopathy / Thyroid Eye Disease (TED) | Phase 2b | Clinical Pause | Subcutaneous | Opthalmic |
| Immunovant Inc. | Batoclimab | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2b | Ongoing | Intravenous | Neurology |
| Immunovant Inc. | Batoclimab | Thyroid Eye Disease (TED) | Phase 3 | Ongoing | Intravenous | Opthalmic |
| Immunovant Inc. | IMVT-1402 | Autoimmune diseases, Graves' Disease | Phase 3 | Ongoing | Subcutaneous | Immunology |
| Immunovant Inc. | Batoclimab | Graves' Disease | Phase 3 | Trial Planned | Intravenous | Endocrinology |
| Immunovant Inc. | Batoclimab (IMVT-1401) | Myasthenia Gravis (MG) | Phase 3 | Data Released | Subcutaneous | Neurology |
| Immunovant Inc. | Batoclimab (IMVT-1401) | Thyroid eye disease (TED) | Phase 3 | Ongoing | Subcutaneous | Opthalmic |
| Immuron Limited | Campylobacter ETEC Therapeutic | Campylobacteriosis | Phase 2 | Oral | N/A |